Adverse reaction forms
This article was originally published in The Tan Sheet
Executive Summary
Public Citizen's Health Research Group urges FDA in April 12 comments to delay development of a common reporting form for adverse incidents involving drugs, medical devices and biologics. HRG recommends that FDA first conduct a six-month field study comparing the effectiveness of the new form to existing forms. HRG asserts that new forms "should be adopted only after the agency has sufficient evidence that they will improve compliance among mandatory and voluntary reporters." FDA currently is in the process of developing an adverse drug reaction reporting system for OTCs.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning